Log in

NYSE:CBMCambrex Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$59.99
0.00 (0.00 %)
(As of 12/5/2019)
Add
Compare
Today's Range
$59.99
Now: $59.99
$59.99
50-Day Range
$59.99
MA: $59.99
$59.99
52-Week Range
$33.80
Now: $59.99
$60.29
VolumeN/A
Average Volume218,726 shs
Market Capitalization$2.02 billion
P/E Ratio21.66
Dividend YieldN/A
Beta2.14
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.
Read More
Cambrex logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.90 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP13201110
Phone201-804-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$532.09 million
Cash Flow$3.91 per share
Book Value$19.48 per share

Profitability

Net Income$92.41 million

Miscellaneous

Employees1,732
Market Cap$2.02 billion
Next Earnings DateN/A
OptionableOptionable

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cambrex (NYSE:CBM) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Cambrex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Cambrex
.

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) released its quarterly earnings data on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.69 by $0.05. The biotechnology company earned $152.05 million during the quarter, compared to analysts' expectations of $132.78 million. Cambrex had a return on equity of 5.38% and a net margin of 5.96%. The business's revenue was up 13.0% on a year-over-year basis. During the same period last year, the firm posted $0.76 earnings per share.
View Cambrex's earnings history
.

What price target have analysts set for CBM?

2 analysts have issued 1 year price objectives for Cambrex's shares. Their forecasts range from $60.00 to $60.00. On average, they expect Cambrex's share price to reach $60.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price.
View analysts' price targets for Cambrex
.

Has Cambrex been receiving favorable news coverage?

Media headlines about CBM stock have trended somewhat negative on Tuesday, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cambrex earned a daily sentiment score of -1.7 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about Cambrex
.

Who are some of Cambrex's key competitors?

What other stocks do shareholders of Cambrex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), CVS Health (CVS), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Broadcom (AVGO), Walt Disney (DIS) and Under Armour (UAA).

Who are Cambrex's key executives?

Cambrex's management team includes the following people:
  • Mr. Steven M. Klosk, Pres, CEO & Director (Age 62)
  • Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 53)
  • Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 53)
  • Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 41)
  • Mr. James G. Farrell, VP & Corp. Controller (Age 52)

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

What is Cambrex's stock price today?

One share of CBM stock can currently be purchased for approximately $59.99.

How big of a company is Cambrex?

Cambrex has a market capitalization of $2.02 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.

What is Cambrex's official website?

The official website for Cambrex is www.cambrex.com.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.